Burkina Faso vs Sierra Leone: Average cost of multi drug-resistant tuberculosis treatment
Burkina Faso
159 constant 2022 US$
in 2024
Sierra Leone
369 constant 2022 US$
in 2024
Burkina Faso rank
91st
Sierra Leone rank
88th
Average cost of multi drug-resistant tuberculosis treatment over time
- Burkina Faso
- Sierra Leone
How they compare
Sierra Leone currently reports 369 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso, a difference of 210 constant 2022 US$.
That makes Sierra Leone's figure about 2.3 times Burkina Faso's.
Across all 6 years both countries report, Sierra Leone has been ahead every year.
Burkina Faso ranks 91st and Sierra Leone ranks 88th of 92 countries.
Sierra Leone has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burkina Faso | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 304.33 constant 2022 US$ | 1,403 constant 2022 US$ | 1,099 constant 2022 US$ | Sierra Leone |
| 2020s | 786.33 constant 2022 US$ | 1,564 constant 2022 US$ | 777.33 constant 2022 US$ | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burkina Faso or Sierra Leone?
- Sierra Leone, at 369 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burkina Faso and Sierra Leone?
- 210 constant 2022 US$, with Sierra Leone ahead.
- How many years of comparable data are there for Burkina Faso and Sierra Leone?
- 6 years are reported by both, from 2017 to 2024.
- How do Burkina Faso and Sierra Leone rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burkina Faso ranks 91st and Sierra Leone ranks 88th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.